ArticlePostepy dermatologii i alergologii2026
The mRNA levels of
Article in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a complex, multifactorial inflammatory disease. The multifaceted aetiology and pathophysiology consist of different elements, including genetic and immunological disorders, skin barrier defects, microbiome dysbiosis and environmental interactions. To date, little has been known about the genes involved in the relationship between extracellular matrix (ECM) expression and the pathogenesis of atopic dermatitis. Aim: The aim of our study was to examine the mRNA transcript levels of genes encoding collagen type I, II, III and IV in the skin of atopic dermatitis patients vs. controls and to search for associations with subjective clinical symptoms and disease severity. Material and methods: A total of 18 subjects participated in the study. Nine biopsies were taken from lesions, nine from non-lesional AD skin and nine from healthy volunteers. The mRNA levels of COL1A1, COL2A1, COL3A1 and COL4A1 were determined using real-time RT-PCR. AD severity was evaluated by calculating the SCORAD score and measuring the pruritus intensity using the Visual Analogue Scale (VAS). Results: A significant increase in the mRNA levels of COL3A1 in the study group compared to the control group was associated with an increase in the intensity of clinically reported symptoms as assessed by the SCORAD and the itching scale VAS ( Conclusions: Our results suggest a role for collagen mRNA levels in AD pathogenesis. Further studies are needed to assess its role as a new potential biomarker, as a predictive element for assessing the intensity of AD or as a new target for AD therapy in the era of personalized medicine. The question to be answered is the importance of remodelling processes in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.